Condition: Tumor Immunity · Immunosuppression · Radiofrequency Ablation · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
This description comes directly from the study's public registry record.
Zhe Tang, Dr. · 13757118212 · 8xi@zju.edu.cn
Always discuss trial participation with your own doctor first.
| the Second Affiliated Hospital of Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04150744